The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.
Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.